Novo Nordisk is now suing Hims & Hers Health over claims that the telehealth company’s compounded semaglutide products infringe on patents covering the molecular structure of Wegovy and Ozempic — and internal testing suggests those compounded versions may contain dangerously high levels of impurities not found in the FDA-approved drugs. Filed on February 9, 2026, in the U.S. District Court for the District of Delaware (Case No. 1:26-cv-00143), the patent infringement lawsuit alleges that Hims’ compounded semaglutide products violate US Patent No. 8,129,343, which covers semaglutide’s acylated GLP-1 compound structure and remains protected through 2032. Novo Nordisk is seeking a permanent injunction to stop Hims from selling compounded semaglutide entirely, plus damages for what it calls willful infringement.
This lawsuit marks a significant escalation. It is Novo Nordisk’s first U.S. patent case against a compounder — previous legal actions targeted trademark infringement rather than the drug’s underlying molecular composition. Hims stock fell roughly 18% on the day the suit was filed, adding to an already brutal stretch for shareholders who watched the stock plunge 30–35% back in June 2025 when Novo terminated a partnership with the company. For consumers who purchased compounded semaglutide through Hims, the quality concerns raised in the lawsuit are worth understanding.
Table of Contents
- What Does Novo Nordisk’s Lawsuit Actually Claim About Compounded Semaglutide Quality?
- How Did the Hims and Novo Nordisk Partnership Fall Apart So Quickly?
- The $49 Compounded Semaglutide Pill That Sparked a Federal Response
- What Should Hims Investors Know About the Securities Class Action?
- The FDA Warning Letter and What It Signals for Compounded Drug Consumers
- How This Case Could Reshape the Compounded Drug Market
- What Comes Next for Hims, Novo, and Affected Consumers
- Frequently Asked Questions
What Does Novo Nordisk’s Lawsuit Actually Claim About Compounded Semaglutide Quality?
The core of Novo Nordisk’s argument goes beyond simple patent protection — it challenges whether compounded semaglutide is even a comparable product. According to Novo Nordisk’s internal testing, injectable compounded semaglutide products contained impurity levels as high as 86%, while compounded oral versions contained impurities of up to 75%. To put that in perspective, that means in some tested samples, the majority of what patients were injecting or swallowing was not the intended active ingredient. LC-MS testing identified 32 distinct impurities across six semaglutide bulk drug substances used in compounding that are not present in Novo Nordisk’s FDA-approved medicines. Unknown impurities in some compounded samples reached up to 33% of total content.
That distinction matters because unknown impurities, by definition, have not been studied for their effects on the human body. FDA-approved semaglutide products go through rigorous manufacturing controls and quality testing that compounded versions simply do not undergo. Compounded semaglutide is not FDA-approved and has not been reviewed for safety, effectiveness, or quality — a point the FDA itself has emphasized repeatedly. It is worth noting that Novo Nordisk has an obvious financial interest in discrediting compounders, and these testing results come from the company’s own labs rather than independent third-party analysis. However, the sheer scale of the reported impurity levels — and the fact that 32 novel impurities were identified — is difficult to dismiss entirely, especially when combined with the FDA’s own actions against Hims.
How Did the Hims and Novo Nordisk Partnership Fall Apart So Quickly?
The speed of the collapse between these two companies tells its own story. On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell branded Wegovy directly through its telehealth platform. The deal seemed like a win for both sides — Hims would gain access to legitimate, FDA-approved weight loss medication, and Novo would reach a massive consumer audience. Less than two months later, on June 23, 2025, Novo Nordisk terminated the partnership entirely.
Novo’s stated reason was blunt: it accused Hims of “deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” The implication was that even while Hims was preparing to sell branded Wegovy, it continued marketing and selling compounded semaglutide products — effectively undercutting the very partnership it had just entered. Hims stock plunged approximately 30–35% on the day the termination was announced, wiping out billions in market value. However, if you were a Hims customer during this period, the partnership collapse does not necessarily mean the compounded product you received was harmful. It does mean the company was operating under increasing scrutiny, and the regulatory and legal landscape shifted dramatically. Consumers who experienced adverse effects from compounded semaglutide purchased through Hims should document their experience, retain any remaining product, and consult with a healthcare provider — these records could become relevant as litigation proceeds.
The $49 Compounded Semaglutide Pill That Sparked a Federal Response
On February 5, 2026 — just four days before Novo filed its patent lawsuit — Hims announced a compounded semaglutide oral pill priced at $49 per month for the first month on a five-month plan, with $99 per month thereafter. The pricing was aggressive by design. Novo Nordisk’s FDA-approved oral Wegovy, which launched on January 5, 2026, carried a list price of $149 per month for the starting 1.5mg dose for cash-paying patients, though commercially insured patients could pay as little as $25 per month through savings programs. The $49 price point made headlines immediately, positioning Hims as the affordable alternative in a market where GLP-1 weight loss drugs have become enormously popular but remain expensive for many consumers. The problem was that the compounded pill was pulled from the market after pressure from HHS and the FDA.
The federal intervention signaled that regulators viewed the product not as a legitimate lower-cost alternative, but as an unapproved drug being marketed in a way that could mislead consumers about its safety and regulatory status. This episode illustrates a broader tension in the compounded drug market. Consumers understandably want affordable access to effective medications, and the price gap between compounded and brand-name semaglutide is real. But cost savings become meaningless if the product contains significant impurities or has not been tested for the same safety and efficacy standards as the approved version. The FDA has made its position clear: compounded semaglutide products have not been reviewed for safety, effectiveness, or quality, regardless of price.
What Should Hims Investors Know About the Securities Class Action?
Beyond the patent and regulatory issues, Hims & Hers faces a securities fraud class action that could affect shareholders who bought stock during a specific window. The case, Sookdeo v. Hims & Hers Health, Inc. (Case No. 3:25-cv-05315), was filed on June 25, 2025, in the U.S. District Court for the Northern District of California. The class period covers April 29 through June 23, 2025 — the exact span between the Novo Nordisk partnership announcement and its termination.
The lawsuit alleges that Hims misled investors about the nature and sustainability of its collaboration with Novo Nordisk. The theory is straightforward: Hims announced a deal that boosted its stock price while allegedly knowing (or recklessly disregarding) that its continued sale of compounded semaglutide products would jeopardize the partnership. When Novo pulled out, shareholders absorbed the loss. If you purchased Hims stock between April 29 and June 23, 2025, you may fall within the proposed class. The tradeoff for investors considering joining a securities class action is familiar. Passive class members typically receive a portion of any settlement without doing much beyond filing a claim form. However, individual damages per share tend to be modest in these cases, especially compared to investors who held large positions. Lead plaintiff deadlines in securities cases are time-sensitive, so investors with significant losses should consult with a securities attorney sooner rather than later to understand their options.
The FDA Warning Letter and What It Signals for Compounded Drug Consumers
On September 9, 2025, the FDA issued a warning letter directly to Hims & Hers Health, Inc. regarding its compounded semaglutide products. FDA warning letters are not routine — they represent a formal finding that a company is in violation of federal law and typically follow an investigation. The letter came roughly three months after Novo terminated its partnership with Hims, suggesting that the FDA’s concerns were already building well before the most recent patent lawsuit. Warning letters from the FDA generally require a company to respond within 15 business days with a corrective action plan. If the agency determines the response is inadequate, it can escalate enforcement to include seizures, injunctions, or criminal prosecution.
For consumers, an FDA warning letter is one of the clearest signals that a product carries regulatory risk. It does not necessarily mean every dose sold was dangerous, but it does mean the FDA identified specific violations serious enough to warrant formal action. The limitation here is transparency. FDA warning letters are public, but the full scope of an agency’s investigation — including the specific test results and inspection findings that prompted the letter — may not be fully disclosed. Consumers who relied on Hims’ marketing when purchasing compounded semaglutide may not have had access to the information needed to make a fully informed decision. That information asymmetry is part of what makes the combined regulatory and legal actions against Hims significant.
How This Case Could Reshape the Compounded Drug Market
The Novo Nordisk patent lawsuit against Hims is the first of its kind — a major pharmaceutical company using patent law, rather than just trademark claims, to go after a compounding operation. If Novo succeeds in obtaining a permanent injunction, it would set a precedent that could discourage other compounders from producing semaglutide and potentially other patented compounds. The case essentially tests whether compounders can legally produce versions of drugs whose molecular structure is still under patent protection, not just their brand names.
For the broader compounded drug industry, the outcome matters enormously. Compounding pharmacies have historically operated in a regulatory gray area, filling a legitimate need for customized medications while sometimes pushing into territory that looks more like generic drug manufacturing without FDA approval. A ruling in Novo’s favor would narrow that gray area considerably, at least for patented molecules.
What Comes Next for Hims, Novo, and Affected Consumers
The patent case in Delaware is likely to take months, if not years, to resolve. Novo Nordisk will push for an early injunction to stop Hims from selling compounded semaglutide during the litigation, while Hims will almost certainly challenge the patent’s applicability to compounded formulations. Meanwhile, the securities class action in California will proceed on its own track, with class certification and discovery phases ahead.
For consumers who purchased compounded semaglutide through Hims, the most practical step right now is to consult with an FDA-approved prescriber about transitioning to approved semaglutide products if weight management treatment is ongoing. Novo’s branded oral Wegovy is now available, and insurance coverage for GLP-1 medications has been expanding. The compounded market may continue to shrink as patent enforcement and FDA oversight intensify — and consumers who act early will have more options than those who wait.
Frequently Asked Questions
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded semaglutide is not FDA-approved and has not been reviewed for safety, effectiveness, or quality. Novo Nordisk’s testing found that compounded versions may contain dozens of impurities not present in the approved drugs, with impurity levels reaching as high as 86% in some injectable samples.
Can I still buy compounded semaglutide from Hims?
The compounded semaglutide oral pill that Hims announced at $49 per month was pulled from the market after pressure from HHS and the FDA. The status of other compounded semaglutide products from Hims may change as litigation and regulatory enforcement continue.
Who qualifies for the Hims & Hers securities class action?
The Sookdeo v. Hims & Hers Health class action covers investors who purchased Hims stock between April 29 and June 23, 2025. The case alleges the company misled investors about its Novo Nordisk partnership.
What did the FDA warning letter to Hims cover?
The FDA issued a warning letter to Hims & Hers Health, Inc. on September 9, 2025, regarding its compounded semaglutide products. Specific details of the violations cited are contained in the publicly available letter on the FDA’s website.
How much does FDA-approved oral Wegovy cost?
Novo Nordisk’s FDA-approved oral Wegovy launched on January 5, 2026, at $149 per month for the starting 1.5mg dose for cash-paying patients. Commercially insured patients may pay as little as $25 per month through available savings programs.
What patent does Novo Nordisk claim Hims infringed?
Novo’s lawsuit centers on US Patent No. 8,129,343, titled “Acylated GLP-1 Compounds,” which covers semaglutide’s molecular structure. The patent is protected through 2032.